Zura Bio Q1 net loss widens as expenses rise

Zura Bio

07/05/2026 12:38

Overview

U.S. biotech firm's Q1 net loss widened yr/yr as R&D and G&A expenses increased

Company raised $144 mln in February public offering to support pipeline advancement

Cash and equivalents rose to $225.6 mln, expected to fund operations through at least 2028

Outlook

Zura expects topline data from HS Phase 2 study in Q4 2026

Company expects topline data from SSc Phase 2 study in H1 2027

Zura says cash position expected to fund operations through at least end of 2028

Result Drivers

R&D SPENDING - Higher R&D expenses driven by advancement of Phase 2 tibulizumab clinical programs

G&A COSTS - Increased G&A expenses due to higher compensation and professional fees to support growth and clinical programs

Company press release: ID:nBw2rJZTa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$24.22 mln
Q1 Income from Operations
-$25.50 mln
Q1 Operating Expenses
$25.50 mln
Q1 Pretax Profit
-$24.22 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)